MediciNova Ownership
| MNOV Stock | USD 2.07 0.06 2.99% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 49 M | Current Value 49 M | Avarage Shares Outstanding 32 M | Quarterly Volatility 13.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
MediciNova |
MediciNova Stock Ownership Analysis
About 21.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.84. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MediciNova recorded a loss per share of 0.21. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 31st of October 2006. MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. Medicinova operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. To find out more about MediciNova contact the company at 858 373 1500 or learn more at https://www.medicinova.com.Besides selling stocks to institutional investors, MediciNova also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different MediciNova's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align MediciNova's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
MediciNova Quarterly Liabilities And Stockholders Equity |
|
MediciNova Insider Trades History
Roughly 3.0% of MediciNova are currently held by insiders. Unlike MediciNova's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against MediciNova's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of MediciNova's insider trades
MediciNova Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MediciNova is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MediciNova backward and forwards among themselves. MediciNova's institutional investor refers to the entity that pools money to purchase MediciNova's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-06-30 | 118.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 96.2 K | Barclays Plc | 2024-06-30 | 83.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 71.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 61.3 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 41.1 K | Millennium Management Llc | 2024-06-30 | 24.9 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 20.7 K | Bank Julius Baer & Co. Ltd, Zurich | 2024-06-30 | 17.1 K | Essex Woodlands Health Ventures | 2024-09-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 694.9 K |
MediciNova Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MediciNova insiders, such as employees or executives, is commonly permitted as long as it does not rely on MediciNova's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MediciNova insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Beaver Carolyn over a week ago Acquisition by Beaver Carolyn of 15000 shares of MediciNova at 5.4 subject to Rule 16b-3 | ||
Nagao Hideki over a month ago Acquisition by Nagao Hideki of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | ||
Obrien Geoffrey over three months ago Disposition of 11318 shares by Obrien Geoffrey of MediciNova at 2.46 subject to Rule 16b-3 | ||
Beaver Carolyn over three months ago Acquisition by Beaver Carolyn of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | ||
Beaver Carolyn over three months ago Acquisition by Beaver Carolyn of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | ||
Nagao Hideki over six months ago Acquisition by Nagao Hideki of 20000 shares of MediciNova subject to Rule 16b-3 | ||
Masatsune Okajima over six months ago Exercise of in-the-money or at-the-money derivative position by Masatsune Okajima of 8400 shares of MediciNova | ||
Geoffrey OBrien over six months ago Acquisition by Geoffrey OBrien of 84000 shares of MediciNova subject to Rule 16b-3 |
MediciNova Outstanding Bonds
MediciNova issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MediciNova uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MediciNova bonds can be classified according to their maturity, which is the date when MediciNova has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
MediciNova Corporate Filings
10Q | 13th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 12th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify | |
10K | 15th of February 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.